Albumin accumulating in tumor tissue increases the distribution of paclitaxel in tumor cells and improves the antitumor effects of paclitaxel.[17] After 2 cycles of IC with nab-paclitaxel plus cisplatin and CCRT, the objective response rates were 97.2% and 100%, respectively, for patients with LA-NPC according to Liang et al.[18] Thrombocytopenia (34.3%) and leukopenia (28.6%) were the most common grade 3 to 4 acute AEs throughout treatment. The gene discussed is ALB; the disease is Thrombocytopenia.